Sangamo Therapeutics Reports Q1 2025 Progress and Financials

Sangamo Biosciences ( (SGMO) ) has released its Q1 earnings. Here is a breakdown of the information Sangamo Biosciences presented to its investors.

Sangamo Therapeutics, a genomic medicine company, focuses on developing treatments for neurological diseases through innovative technologies such as zinc finger epigenetic regulators and novel AAV capsid delivery platforms. In its first quarter 2025 earnings report, Sangamo announced significant advancements, including a capsid license agreement with Eli Lilly for CNS disease targets and progress in its Fabry disease gene therapy program. The company reported a net loss of $30.6 million, a decrease from the previous year, with revenues rising to $6.4 million due to collaborations with Pfizer and Sigma-Aldrich. Operating expenses were reduced significantly, reflecting strategic realignment and cost-saving measures. Looking ahead, Sangamo aims to continue advancing its neurology-focused pipeline and secure partnerships for its Fabry disease program, while maintaining financial discipline to extend its operational runway.